BCG-STING

BCG-STING is a preclinical recombinant Bacillus Calmette-Guérin (BCG) strain engineered to overexpress the bioactive STING (Stimulator of Interferon Genes) agonist cyclic di-AMP (c-di-AMP). Developed by researchers at Johns Hopkins University, it is designed as an immunotherapy for non-muscle invasive bladder cancer (NMIBC). By combining the inherent immunogenicity of BCG with the potent activation of the STING pathway, BCG-STING enhances the recruitment and activation of tumor-infiltrating CD4+ and CD8+ T cells and inflammatory macrophages within the tumor microenvironment. In preclinical models of urothelial carcinoma, intravesical administration of BCG-STING demonstrated superior antitumor efficacy and higher rates of complete tumor regression compared to wild-type BCG or small-molecule STING agonists like ADU-S100.

Other names

recombinant Bacillus Calmette-Guérin-OncoSTINGrBCG-STINGOncoSTING-101OncoSTING101OncoSTING 101